Hitomi Hosoya
A5025501559- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Neuroscience and Neural Engineering
- Heart Failure Treatment and Management
- Integrated Circuits and Semiconductor Failure Analysis
- Hematological disorders and diagnostics
- Erythropoietin and Anemia Treatment
- Synthesis and Biological Evaluation
- Molecular Biology Techniques and Applications
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Nanoparticle-Based Drug Delivery
- Iron Metabolism and Disorders
- RNA Interference and Gene Delivery
Stanford University
2021-2025
Palo Alto University
2023-2025
Hospital of the University of Pennsylvania
2017-2020
Pennsylvania Hospital
2017-2020
University of Pennsylvania Health System
2019
The University of Tokyo
2012-2016
University of Tokyo Hospital
2016
The University of Texas MD Anderson Cancer Center
2012-2015
Naval Hospital Yokosuka Japan
2013
Prostate cancer antigen 3 (PCA3) is the most specific prostate biomarker but its function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, which harbors PCA3 locus, thereby classifying as an antisense intronic long noncoding (lnc)RNA. We show that controls PRUNE2 levels via unique regulatory mechanism involving formation of PRUNE2/PCA3 double-stranded RNA undergoes adenosine deaminase acting on (ADAR)-dependent adenosine-to-inosine editing. expression or...
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines therapy. On KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize within 100 days ide-cel standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data censored at day 100. Grade cytopenia present among 65% 30 40% 90. Granulocyte colony...
Abstract Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 CD22 (CAR19-22), which was well tolerated associated with high response rates but common. Interleukin-15 (IL15) induces proliferation diverse immune cells can augment lymphocyte trafficking. Here, we...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
Significance The main goal in the emerging field of cancer nanomedicine is to generate, standardize, and produce multifunctional carriers designed improve response drugs against tumors. Here we report design, development, preclinical validation a ligand-directed bioinorganic platform that integrates tumor targeting, receptor-mediated cell internalization, photon-to-heat conversion, drug delivery. This enabling hydrogel-based technology can accommodate broad variety ligands, nanoparticles,...
We evaluated patients with relapsed multiple myeloma renal impairment (RI) treated standard of care idecabtagene vicleucel (ide-cel), as outcomes chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined creatinine clearance (CrCl) <50 mL/min. CrCl <30 mL/min or dialysis dependence were severe RI. The study cohort included 214 patients, 28 (13%) RI, including 11 (dialysis, N=1). Patients older, more likely to be female and had higher likelihood...
Circulating cancer cells can putatively colonize distant organs to form metastases or reinfiltrate primary tumors themselves through a process termed "tumor self-seeding." Here we exploit this biological attribute deliver tumor necrosis factor alpha (TNF), potent antitumor cytokine, directly and metastatic in mechanism that have defined as self-targeting." For purpose, genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), Lewis lung carcinoma produce release murine...
Despite advances in treatments, multiple myeloma (MM) remains an incurable cancer where relapse is common. We developed a circulating tumor DNA (ctDNA) approach order to characterize genomics, monitor treatment response, and detect early MM. By sequencing 412 specimens from 64 patients with newly diagnosed or relapsed/refractory disease, we demonstrate the correlation between ctDNA key clinical biomarkers, as well patient outcomes. further extend our simultaneously track CAR-specific...
Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well-characterized given the exclusion these from clinical trials. Herein, we evaluated relapsed/refractory multiple myeloma and RI treated standard-of-care teclistamab. was defined as creatinine clearance (CrCl) &lt;40mL/min. CrCl &lt;30mL/min or dialysis dependence were severe RI. Of 384 included patients, 81 (21%) had RI, including 45 (18%) 18 (5%) on dialysis. Patients more likely to be older (median...
Abstract Introduction: Localized cancers are increasingly treated with neoadjuvant therapies prior to resection. For operable breast cancers, this approach can aid in breast-conservation, therapeutic response assessment, and prognostication. patients residual disease, addition of adjuvant therapy reduce recurrence risk improve outcomes. Pathological assessments responses, however, imperfectly predict survival, resulting under- over-treatment many patients. Current liquid biopsies also...
Phage display screening allows the study of functional protein–protein interactions at cell surface, but investigating intracellular organelles remains a challenge. Here we introduce internalizing-phage libraries to identify clones that enter mammalian cells through receptor-independent mechanism and target-specific as tool select ligand peptides their receptors. We demonstrate penetratin, an antennapedia-derived peptide, can be displayed on phage envelope mediate uptake internalizing into...